Welcome to our dedicated page for QT Imaging Holdings news (Ticker: QTIH), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
QT Imaging Holdings, Inc. (OTCQB: QTIH) is a medical device company focused on body imaging systems that use low frequency sound waves, with a particular emphasis on breast imaging. The company’s news flow centers on the commercialization of its QTI Breast Acoustic CT™ scanner, a breast imaging system described as radiation-free, contrast-free, and compression-free, as well as on the evolution of its cloud-enabled imaging platform.
On this page, readers can follow company announcements about scanner shipments and revenue milestones, including updates that link revenue growth to the number of QTI Breast Acoustic CT™ scanners shipped. QT Imaging’s press releases also provide details on distribution agreements with partners such as NXC Imaging, Inc., a subsidiary of Canon Medical Systems USA, and Gulf Medical Co. in Saudi Arabia, which are referenced in connection with shipment plans and revenue outlooks.
Investors and healthcare professionals can review financial result announcements, where QT Imaging discusses quarterly revenue, year-over-year growth, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with commentary on its financial position and capital structure. News items also cover capital markets activities, including a private placement (PIPE) financing and a 3:1 reverse stock split, as well as the company’s stated intention to pursue a relisting on the Nasdaq Capital Market.
Beyond financial and corporate updates, QT Imaging issues news about technology collaborations and clinical outreach. Examples include a strategic collaboration with Intelerad Medical Systems to deploy cloud-based PACS across its research and commercial networks, and participation in the RSNA annual meeting with seminars on quantitative transmission imaging and live demonstrations of its FDA-cleared Breast Acoustic CT™ scanner. Visitors can use this news feed to track how QT Imaging is advancing its imaging technology, expanding distribution, and developing its cloud SaaS and AI/ML capabilities over time.
Summary not available.
QT Imaging (OTCQB: QTIH) announced a collaboration with Olea Medical to integrate Olea’s advanced visualization, validated quantitative analytics and AI-ready imaging technologies into QT Imaging’s Cloud SaaS platform delivered via InteleShare.
The combined solution will enable secure cloud delivery of QT Imaging Breast Acoustic CT studies with high-performance 3D/4D visualization, subtraction tools, segmentation and volumetric analysis, multimodality integration (mammography, DBT, ultrasound, MR, QT Imaging) and support for centralized multi-institutional research and clinical trial workflows.
QT Imaging (OTCQB: QTIH) entered an exclusive distribution agreement with Al Naghi Medical for the United Arab Emirates to sell QTI Breast Acoustic CT scanners and the QTI Cloud Platform. The deal requires minimum orders of 7 scanners in 2026 (shipments start Q2'26), 16 in 2027, and 20 in 2028—a total minimum of 43 scanners and over $24 million in revenue. The agreement follows a recent exclusive deal for Saudi Arabia and targets a UAE market with rising breast cancer prevalence and younger median diagnosis age.
QT Imaging (OTCQB: QTIH) confirmed it shipped 40 Breast Acoustic CT scanners in 2025 (up from 12 in 2024) and met its revenue guidance of more than $18 million for 2025. The company projects year-end cash of at least $10 million, versus $1.2 million at the end of 2024, and reported enhanced profitability and meaningful debt reduction via unaudited pro forma statements filed on Form 8-K on December 23, 2025.
QT Imaging reiterated a $39 million revenue target for 2026 tied to shipment of 80 scanners under amended distribution agreements with NXC Imaging (Canon Medical Systems USA) and Gulf Medical Co.
QT Imaging (OTCQB: QTIH) reported $4.2M revenue in Q3 2025, driven by shipment of 9 QTI Breast Acoustic CT scanners, up 339% YoY and 15% QoQ. The company reaffirmed its 2025 revenue target of $18M (shipment of 40 scanners) and raised 2026 guidance to $39M (80 scanners) after a new Saudi Arabia distribution agreement. QT Imaging closed a $18.2M October PIPE, repaid $5M of a term loan, repurchased a warrant, and had $1.7M cash at Sept 30 (pre-Pipe). Management added CFO Jay Jennings and CCO Satrajit Misra, filed to relist on Nasdaq and completed a 3:1 reverse split effective Oct 23, 2025.
QT Imaging (OTCQB: QTIH) appointed Satrajit Misra as Chief Commercial Officer effective November 10, 2025. The newly created CCO role will lead commercial scale-up and clinical partnerships as the company pivots toward a SaaS and biomarker-driven franchise and seeks wider adoption of its radiation-free, contrast-free, compression-free breast imaging technology.
Misra brings ~30 years of radiology, oncology and molecular imaging experience, most recently as Executive SVP, Chief Sales and Marketing Officer at Canon Medical Systems USA, and prior roles at Philips and Siemens. He will focus on accelerating product pipeline development, market expansion, and shareholder value.
QT Imaging (OTCQB: QTIH) will release its third quarter 2025 financial results after market close on Tuesday, November 11, 2025. Management will host a webcasted conference call the same day to review results and provide a business update.
Conference call details: 4:30 p.m. ET; domestic dial-in 1-877-545-0523; international dial-in 973-528-0016; access code 457613. The call will be broadcast live and archived on the company website.
QT Imaging (OTCQB: QTIH) will present at RSNA 2025 in Chicago, Nov 30–Dec 4, 2025. Chief Medical Officer Elaine luanow, MD will deliver a seminar titled “Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound” on Dec 3 at 1:00 PM CT at the Canon Workshop (Booth #8349, North Hall).
Attendees are invited to live demonstrations of the company’s FDA-cleared QTI Breast Acoustic CT scanner at Booth #6713, a non‑invasive 3D breast imaging system that requires no compression, contrast, or ionizing radiation.
QT Imaging (OTCQB: QTIH) announced a strategic collaboration with Intelerad Medical Systems on October 28, 2025 to deploy InteleShare Research PACS and Cloud PACS across QT Imaging’s clinical research and commercial networks.
The partnership enables browser-based viewing, image anonymization, secure cloud archiving, EHR integration, and multi-institutional data sharing for QT Imaging’s Breast Acoustic CT scanners. QT Imaging plans to deliver its Cloud SaaS platform and future AI/ML modules (automated lesion segmentation, volumetric tissue characterization, diagnostic support) via InteleShare’s DICOM-compatible cloud architecture to connected systems.
QT Imaging (OTCQB: QTIH) implemented a 3:1 reverse stock split of its common stock that became market effective on October 24, 2025. The company disclosed that FINRA referenced the market effectiveness in its Form 8-K dated October 23, 2025.
Public warrants were adjusted so each warrant is exercisable for 0.33333809 shares and the warrant exercise price was increased on a 2.9999572:1 basis from $2.30 to $6.90. Continental Stock Transfer and Trust Company is acting as exchange agent; book-entry holders need take no action, while certificated holders will receive a letter of transmittal with surrender instructions.